文献速递炎症性肠病

基于治疗药物监测的主动给药与临床给药对接受英夫利西单抗治疗的儿童克罗恩病内镜愈合的对比

Proactive Drug Monitoring Versus Clinically Based Dosing for Endoscopic Healing in Pediatric Crohn's Disease Receiving Infliximab.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-05-14

这项在韩国4个中心开展的非盲随机对照试验纳入112例对英夫利西单抗诱导治疗有应答的初治生物制剂儿童克罗恩病患者,比较基于主动治疗药物监测给药与临床给药。第54周时主动组内镜愈合率80.0%(40/50)高于临床组57.1%(28/49)(P = .025);主动组持续无激素临床缓解率89.3%(50/56)高于临床组69.6%(39/56)(P = .019)。

要点

  • 主动治疗药物监测组第54周内镜愈合率80.0%(40/50)高于临床给药组57.1%(28/49)(P = .025)。
  • 主动组持续无激素临床缓解率89.3%(50/56)高于临床组69.6%(39/56)(P = .019)。
  • 多因素分析中主动给药与内镜愈合(OR 3.48,95%CI 1.26-10.43)和持续无激素临床缓解(OR 5.50,95%CI 1.72-21.61)独立相关。

核心结论

  • 在儿童克罗恩病随机对照试验中,基于主动治疗药物监测的英夫利西单抗给药在内镜愈合方面优于临床给药。

研究设计与样本

  • 非盲随机对照试验,纳入112例对英夫利西单抗诱导治疗有应答的初治生物制剂儿童克罗恩病患者,来自韩国4个中心,时间为2017年7月至2020年11月。
  • 患者随机分为基于主动治疗药物监测给药组(主动组)或临床给药组(临床组),主要终点为第54周内镜愈合。

主要发现

  • 第54周内镜愈合率主动组为80.0%(40/50),临床组为57.1%(28/49),P = .025。
  • 第54周持续无激素临床缓解率主动组为89.3%(50/56),临床组为69.6%(39/56),P = .019。
  • 多因素logistic回归分析显示,干预分组(主动组 vs 临床组)与内镜愈合独立相关(OR 3.48,95%CI 1.26-10.43,P = .019)。
  • 多因素logistic回归分析显示,干预分组(主动组 vs 临床组)与持续无激素临床缓解独立相关(OR 5.50,95%CI 1.72-21.61,P = .007)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Proactive dosing based on therapeutic drug monitoring (TDM) of adalimumab is associated with higher rates of sustained corticosteroid-free clinical remission (SCFCR) in children with Crohn's disease (CD) than that with reactive TDM. We aimed to investigate whether proactive dosing of infliximab (IFX) based on TDM is associated with higher rates of endoscopic healing (EH) in pediatric patients with CD than that with clinically based dosing. METHODS: We conducted a non-blinded, randomized controlled trial of 112 biologic-naïve children with CD who had responded to IFX induction treatment at 4 centers in South Korea between July 2017 and November 2020. Patients were randomly assigned to receive dosing based on proactive TDM (proactive arm) or clinically based dosing (clinical arm). The primary endpoint was EH at week 54. RESULTS: The primary endpoint was achieved in 80.0% (40/50) of the proactive arm and 57.1% (28/49) of the clinical arm (P = .025). SCFCR was achieved in 69.6% (39/56) of the clinical arm and 89.3% (50/56) of the proactive arm at week 54 of treatment (P = .019). According to the multivariate logistic regression analysis, the intervention group (proactive arm vs clinical arm) was an independent factor associated with EH (odds ratio, 3.48; 95% confidence interval, 1.26-10.43; P = .019) and SCFCR (odds ratio, 5.50; 95% confidence interval, 1.72-21.61; P = .007). CONCLUSIONS: Dosing based on proactive TDM was superior to clinically based dosing in terms of EH in a randomized controlled trial of pediatric CD. Trial identifier: cris.nih.go.kr: KCT0005190.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kang B, Kim ES, Choi S, et al. Proactive Drug Monitoring Versus Clinically Based Dosing for Endoscopic Healing in Pediatric Crohn's Disease Receiving Infliximab. Clin Gastroenterol Hepatol. 2025. PMID: 40378994. doi:10.1016/j.cgh.2025.04.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。